The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Perioperative COX2 and β‐adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial
Abstract
Background: Preclinical studies have implicated excess release of catecholamines and prostaglandins in the mediation of prometastatic processes during surgical treatment of cancer. In this study, we tested the combined perioperative blockade of these pathways in patients with colorectal cancer (CRC). Methods: In a randomized, double‐blind, placebo‐controlled biomarker trial involving 34 patients, the β‐blocker propranolol and the COX2‐inhibitor etodolac were administered for 20 perioperative days, starting 5 days before surgery. Excised tumors were subjected to whole genome messenger RNA profiling and transcriptional control pathway analyses. Results: Drugs were well‐tolerated, with minor complications in both the treatment group and the placebo group. Treatment resulted in a significant improvement ( P < .05) of tumor molecular markers of malignant and metastatic potential, including 1) reduced epithelial‐to‐mesenchymal transition, 2) reduced tumor infiltrating CD14 + monocytes and CD19 + B cells, and 3) increased tumor infiltrating CD56 + natural killer cells. Transcriptional activity analyses indicated a favorable drug impact on 12 of 19 a priori hypothesized CRC‐related transcription factors, including the GATA, STAT, and EGR families as well as the CREB family that mediates the gene regulatory impact of β‐adrenergic– and prostaglandin‐signaling. Alterations observed in these transcriptional activities were previously associated with improved long‐term clinical outcomes. Three‐year recurrence rates were assessed for long‐term safety analyses. An intent‐to‐treat analysis revealed that recurrence rates were 12.5% (2/16) in the treatment group and 33.3% (6/18) in the placebo group ( P = .239), and in protocol‐compliant patients, recurrence rates were 0% (0/11) in the treatment group and 29.4% (5/17) in the placebo group ( P = .054). Conclusions: The favorable biomarker impacts and clinical outcomes provide a rationale for future randomized placebo‐controlled trials in larger samples to assess the effects of perioperative propranolol/etodolac treatment on oncological clinical outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a similar trial by Haldar et al., in 34 patients with colorectal cancer there was also a markedly reduction of recurrences in the treatment group with propranolol and etodolac (12.5%) compared to the placebo group (33.3%) [22].”
From Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial (2025) · cites this paper as [22]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,985
Steptoe, A., Hamer, M., & Chida, Y. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.03.011 · Cited by 1,278
Sympathetic nervous system regulation of the tumour microenvironment
Cole, S. W., Nagaraja, A. S., Lutgendorf, S. K., Green, P. A., & Sood, A. K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3978 · Cited by 576
Self-citationPerioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556
Exploiting the critical perioperative period to improve long-term cancer outcomes
Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487
Self-citationQuantitative evidence for early metastatic seeding in colorectal cancer
Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J. A., Shaffer, J. S., Suarez, C. J., Berghoff, A. S., Cremolini, C., Falcone, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0423-x · Cited by 480
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
Reinert, T., Schøler, L. V., Thomsen, R., Tobiasen, H., Vang, S., Nordentoft, I., Lamy, P., Kannerup, A.-S., Mortensen, F. V., Stribolt, K., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308859 · Cited by 467
COX-2: A Molecular Target for Colorectal Cancer Prevention
Brown, J. R., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.051 · Cited by 444
Flagged first, then by citations
Research works printed but not linked: 1
- Ferlay J, 2018, Global and Regional Estimates of the Incidence and Mortality for 38 Cancers: GLOBOCAN 2018
Cited by
Sorted by citations
Items 101–123 of 123
The Role of Catecholamines (Epinephrine/Norepinephrine) and Beta Blocker in Head and Neck Cancer
Kim, M. (2023) · Korean Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.3342/kjorl-hns.2023.00570
Yang, Y., Feng, M., Bai, L., Liao, W., Zhou, K., Zhang, M., Wu, Q., Wen, F., Lei, W., Zhang, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16625488
Influencing the Efficacy of Anticancer Treatments
Mravec, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-68590-3_55
Mravec, B. (2024) · Springer eBooks · doi:10.1007/978-3-031-68590-3_43
Neuroimmune Communications in Cancer
Abbadi, J., Carr, D. J. J., & Cox, M. A. (2024) · Integrated science · doi:10.1007/978-3-031-72079-6_24
Escitalopram facilitates tumor growth and metastasis in rodents: Is it safe?
Azan, Y., Margalit, A., Wiener, G., Sandbank, E., Doron, R., Sorski, L., Rosenne, E., Polsky, A. L., Gilam, A., Eckerling, A., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101182
“In the perioperative context, these drugs, separately and combined, were shown both by translational and recent clinical studies to improve biomarkers of cancer progression, as well as long-term cancer outcomes [72 – 75].”
Self-citationHu, T., Liu, C.-J., Yin, X., Tang, W., Yin, L., Bai, H., Liu, F., Wang, D., & Li, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26610375
Chen, Q., Li, M., Chen, J., Huang, Z., Chen, X., Zhao, H. Y., & Cai, J. (2022) · Figshare · doi:10.6084/m9.figshare.20652307
Pei, Y., Wang, Z., Zheng, Y., Wang, Z.-Y., Cao, C.-W., Liang, H.-J., Wang, B.-Y., Jin, Z.-J., Lin, S.-Y., Chen, L., et al. (2026) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.10.001
Shvalbo, B. B., Scarlat, S., Sakis, N., Trachtenberg, E., Sandbank, E., Weil, M., Eckerling, A., Cole, S. W., & Ben‐Eliyahu, S. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101228
“…surgery, it remains unclear whether psychologically induced stress-inflammatory responses have unique deleterious impacts on long-term cancer outcomes, and whether their blockade would be beneficial beyond addressing the physiological effects of surgery (Haldar et al., 2020; Hiller et al., 2020).”
Self-citationZhou, L. E. T. A. O., Luo, X., Bao, T., Sun, H., He, C., Yang, Y., & Xia, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004144
Neuro-immune interactions in cancer: mechanisms and therapeutic prospects
Liu, J., Zhang, C., ZHANG, C., Pei, J., & Li, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1729908
Regulation of solid tumors by the peripheral nervous system
Chang, A., Zhu, S., Lam, T., & Sloan, E. K. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20251333
Anesthesia and Cancer Research
West, R., & Ma, D. (2026) · Springer eBooks · doi:10.1007/978-3-032-19175-5_28
Rogacz, Z., Pacuła, W., Janas, W., Markiewka, M., Wala, P., Madej, M., & Strzałka‐Mrozik, B. (2026) · Cancers · doi:10.3390/cancers18152507
“…biopsy analyses, including circulating tumor DNA (ctDNA), extracellular vesicles, and exosomal biomarkers, may provide valuable insights into the biological effects of β -blocker therapy, facilitate biomarker-guided patient selection, and improve the design of future precision oncology trials [53].”
InfluentialYe, L., Shen, H., 林锦源, 裴圣林, Lin, F., Li, X., Chang, E., & Pan, L. (2026) · Holistic Integrative Oncology · doi:10.1007/s44178-026-00280-x
Neuronal regulation of cancer: Mechanisms, functional consequences and therapeutic opportunities
Liu, S., Cao, C., Zhu, C., Gui, L., & Wu, P. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189693
Antitumour Effects of β-Blockers: A Narrative Review of the Literature
Melissaridou, D., Savvidou, O. D., Lianou, I., Kaspiris, A., Korkolopoulou, P. A., Papadimitriou, Ε., & Papagelopoulos, P. J. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48090865
Sivanesan, S., Ramberg, H., Kristiansen, T., Thapa, S. B., Bjøre, M., Berge, V., Ottosson, F., Brennhovd, B., Storås, A. H., Thorsby, P. M., et al. (2026) · BJUI Compass · doi:10.1002/bco2.70267
Liu, J., Shen, Y., Liao, J., Wang, X., Mao, Z., Wang, Y., & Zhang, P. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1942309
Neuro-immune interactions in tumors, immune-related disorders, and infections
Zhuang, Q.-Y., Zhang, S.-W., Shao, Z., Xiao, Y., & Jiang, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02842-x
Tudoraşcu, D. R., Vere, C. C., Petrescu, M., Ciurea, A.-M., Pana, R. C., Dan, A. O., Târtea, E. A., Greșiță, A., Hădăreanu, D.-R., Obleagă, C. V., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209090
Neuron–tumor communication as a target for neuromodulatory drug delivery in cancer
Esa, M., Ahmad, T., Khan, M., & Rahman, A. U. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1929593
Metadata
- Authors
- Haldar, R., Ricon‐Becker, I., Radin, A., Gutman, M., Cole, S. W., Zmora, O., & Ben‐Eliyahu, S.
- Affiliations
- Tel Aviv University (IL)
- University of California, Los Angeles (US)
- Sheba Medical Center (IL)
- Assaf Harofeh Medical Center (IL)
- Corresponding author
- Ben‐Eliyahu, Shamgar
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2020-06-13
- Volume
- 126
- Issue
- 17
- Pages
- 3991-4001
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W3035075055
- Cited by
- 122
- References
- 47
- Citations by year
- 2026: 24 · 2025: 17 · 2024: 13 · 2023: 22 · 2022: 25 · 2021: 16 · 2020: 5
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Israel Science Foundation (1406/10)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, perioperative therapy, propranolol, etodolac, COX-2 inhibition, beta-adrenergic blockade, catecholamines, prostaglandins, metastasis, epithelial-mesenchymal transition, tumor-infiltrating immune cells, natural killer cells, CD14+ monocytes, CD19+ B cells, tumor recurrence, gene expression profiling, transcription factors, GATA, STAT, EGR, CREB
- MeSH terms
- Adrenergic beta-Antagonists, Adult, Aged, Female, Humans, Immunity, Innate, Inflammation, Killer Cells, Natural, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Biomarkers, Tumor, Colorectal Neoplasms, Signal Transduction, Cell Line, Tumor, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
